新的抗凝血剂用于治疗静脉血栓塞栓症
1McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. jweitz@thrombosis.hhscr.org
Circulation
|September 2, 2004
概括
新的抗凝血剂通过使口服药物可供使用并减少监测需求,改善了静脉血栓栓塞 (VTE) 治疗. 这些新型药物简化了VTE的治疗,克服了传统的氨酸和维生素K抗剂治疗的局限性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 静脉血栓塞栓症 (VTE) 治疗传统上涉及亲肠道抗凝剂,如氨酸或低分子量氨酸 (LMWH) 与维生素K对抗剂相结合.
- 目前的VTE治疗需要至少5天的双重治疗,直到达到治疗性抗凝固.
- 限制包括不方便的LMWH皮下注射和对维生素K对抗剂的常规凝血监测.
研究的目的:
- 引入和评估旨在克服传统VTE疗法的局限性的新型抗凝剂.
- 突出新型抗凝剂的优势,包括口服,可预测的反应和减少监测要求.
- 为了比较 fondaparinux,idraparinux 和 ximelagatran 与现有治疗方法的机制和潜在益处.
主要方法:
- 对最近推出的抗凝剂的审查: fondaparinux,idraparinux (合成糖类类似物) 和ximelagatran (口服血栓抑制剂).
- 分析它们的药理动力学和药理动力学特性,包括作用开始和需要监测.
- 评估它们的安全性,特别是关于肝素诱导的血小板缺血 (HIT) 和抗剂的可用性.
主要成果:
- 新的药物,如芬达巴鲁努克斯,伊德拉巴鲁努克斯和西米拉加特兰提供可预测的抗凝剂反应,消除了常规凝血监测的需要.
- 芬达巴鲁努克斯和伊德拉巴鲁努克斯不会引起肝素诱导的血小板缩 (HIT),因为它们不会与血小板或血小板因子4结合.
- 齐米拉加特兰提供了快速的起作用,在治疗开始时无需同时使用肠道抗凝剂.
结论:
- 新型抗凝血剂在静脉血栓炎的治疗方面取得了重大进展,为患者提供了更好的方便性和安全性.
- 芬达帕鲁努克斯,伊德拉帕鲁努克斯和西米拉加特兰解决了传统疗法的关键局限性,简化了治疗方案.
- 对这些新药,特别是伊德拉帕鲁努克斯,缺乏易于获得的解药仍然是临床应用的考虑因素.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:30Venous Thrombosis I: Introduction
818
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
818
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
01:30Venous Thrombosis IV: Nursing Management
415
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
415
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
748
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
748